In TRAIL related cancer therapeutics, recombinant soluble form of TRAIL, rhTRAIL (Dulanermin), the TRAIL R1-targeting agonistic monoclonal antibody mapatumumab; and the TRAIL R2-targeting agonistic monoclonal antibodies conatumumab, tigatuzumab, HGS-ETR-2 (lexatumumab), and DAB4 (PRO95780) against different types of cancer including non-Hodgekin lymphoma and colorectal cancer have been advanced to clinical development as chemotherapeutic agents (210). Here, TNFSF10 is linked to cancer.